Deerfield Management Co is the biggest holder of Akari Therapeutics, Plc (AKTX)

Akari Therapeutics, Plc (NASDAQ:AKTX) reached 132.47% versus a 1-year low price of $3.44. The stock was last seen 22.72% higher, reaching at $7.4 on Oct. 11, 2017. At recent session, the prices were hovering between $6.2 and $8.04. This company shares are 18.24% off its target price of $8.75 and the current market capitalization stands at $88.58M. The recent change has given its price a 51.53% lead over SMA 50 and -66.67% deficit over its 52-week high. The stock witnessed 26.5% gains, 60.87% gains and -54.93% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AKTX’s volatility during a week at 15.56% and during a month it has been found around 19.42%.

Akari Therapeutics, Plc (AKTX) Top Holders

Institutional investors currently hold around $20 million or 26.5% in AKTX stock. Look at its top three institutional owners. Deerfield Management Co owns $4.93 million in Akari Therapeutics, Plc, which represents roughly 5.57% of the company’s market cap and approximately 24.67% of the institutional ownership. Similar statistics are true for the second largest owner, Vivo Capital, Llc, which owns 527,842 shares of the stock are valued at $3.18 million. The third largest holder is Baker Bros. Advisors Lp, which currently holds $3 million worth of this stock and that ownership represents nearly 3.38% of its market capitalization.

Akari Therapeutics, Plc 13F Filings

At the end of June reporting period, 7 institutional holders increased their position in Akari Therapeutics, Plc (NASDAQ:AKTX) by some 359,154 shares, 8 decreased positions by 575,665 and 5 held positions by 2,383,709. That puts total institutional holdings at 3,318,528 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 295,991 shares while 4 institutional investors sold out their entire positions totaling 142,288 shares.

Akari Therapeutics, Plc (AKTX) Analyst Guide

Several analysts have released their opinion on Akari Therapeutics, Plc (NASDAQ:AKTX), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.

Previous articleLooking At The Big Picture: Seabridge Gold Inc. (SA), Endologix, Inc. (ELGX)
Next articleTop Institutional Investors That Own MabVax Therapeutics Holdings, Inc. (MBVX)